The FDA's refusal to file the NDA for etripamil nasal spray is a major regulatory setback for Milestone Pharmaceuticals, likely leading to a negative investor sentiment and a potential decrease in stock price in the short term. The news directly impacts the company's ability to bring the drug to market, which is critical for its revenue prospects and growth strategy.